drug
risdiplam
Marketedupdated 5mo agoby Genentech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(0)
nothing on the calendar yet
Trials studying risdiplam
- phase4Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
- phase4A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
- phase2A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
- phase4A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
- phase2A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
- phase2A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
- phase3A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
- —Investigating NMJ Defects in SMA Following Central and Peripheral SMN Restoration
News(2)
- Roche launches simultaneous screening test for SMA, SCID, and SCDRoche Diagnostics has launched a new in vitro diagnostic test for newborn screening to detect a series of rare disorders.fiercebiotech · 5h ago
- Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugsRoche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.fiercebiotech · 7d ago
Data sources
last refreshed 45m ago
Found something off?
comments(0)
5-min edit window · permanent after that